A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms

British Journal of Cancer

Volumn 108, Issue 9, 2013, Pages 1838-1845

  Khan, M S ^a,b   Luong, T V ^a   Watkins, J ^a   Toumpanakis, C ^a   Caplin, M E ^a   Meyer, T ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Carcinoid tumour; Ki 67 antigen; Mitotic count; Neuroendocrine tumour; Prognosis; Tumour grading

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CELL COUNT; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDGUT NEUROENDOCRINE NEOPLASM; MITOTIC COUNT; NEOPLASM; OVERALL SURVIVAL; PANCREAS METASTASIS; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878617649     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.156     Document Type: Article

References (40)

1. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS, Los J, Peterse HC, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JG (1989) The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185(5): 664-670.
2. Bergers E, Jannink I, van Diest PI, Cuesta MA, Meyer S, van Mourik JC, Baak JP (1997) The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Human Pathol 28(1): 95-100.
3. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO Classification of Tumours of the Digestive System. IARC: Lyon.
4. Donhuijsen K, Schmidt U, Hirche H, van Beuningen D, Budach V (1990) Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Human Pathol 21(7): 709-714.
5. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. J Natl Cancer Institute 103(22): 1656-1664.
6. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16(2): 585-597.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247.
8. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14(23): 7798-7803.
9. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G (2007) The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J cancer 96(8): 1178-1182.
10. Furlan D, Cerutti R, Uccella S, La Rosa S, Rigoli E, Genasetti A, Capella C (2004) Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 10(3): 947-957.
11. Goodell PP, Krasinskas AM, Davison JM, Hartman DJ (2012) Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol 137(4): 576-582.
12. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediategrade groups. J Clin Oncol 20(11): 2633-2642.
13. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape UF (2011) Neuroendocrine tumors of midgut and hindgut origin: tumornode- metastasis classification determines clinical outcome. Cancer 117(15): 3332-3341.
14. Khan MS, Caplin ME (2011) Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18(Suppl 1): S53-S74.
15. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6): 707-712.
16. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6): 735-752.
17. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1): 1-18vii.
18. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97(4): 934-959.
19. Oberg K, Anthony L, Sideris L, Chen LT, Cherfi A, Tsuchihashi Z, Winkler R, de Vries EG (2011) Role of Chromograning A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PC) in Patients with Advanced Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results. In 8th Annual European Neuroendocrine Tumour Society (ENETS) Conference for the Diagnosis and Management of Neuroendocrine Tumour Disease p C81.
20. Lisbon. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4): 1083-1092.
21. Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B (2008a) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4): 1083-1097.
22. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G, Wiedenmann B (2008b) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2): 256-265.
23. Paulus G, Hong LX, Atassi G, Buyssens N (1984) Regional variations in proliferation rate and degree of differentiation in B16 melanomas. Virchows Arch B Cell Pathol Incl Mol Pathol 46(1-2): 43-52.
24. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G (1996) Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathol 27(11): 1124-1134.
25. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1): 6-32.
26. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4): 395-401.
27. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4): 757-762.
28. Rorstad O (2005) Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 89(3): 151-160.
29. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6): 824-833.
30. Sobin LH, Gospodarowicz MK, Wittekind C (2009) UICC: TNM classification of malignant tumours. 7th edn. Wiley-Blackwell: Oxford, UK.
31. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L (2009) Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Human Pathol 40(9): 1262-1268.
32. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK (2010) The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39(6): 799-800.
33. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R (2005) Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 16(11): 1806-1810.
34. Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB, Van Velthuysen ML (2002) Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Human Pathol 33(11): 1126-1132.
35. Verhoeven D, Bourgeois N, Derde MP, Kaufman L, Buyssens N (1990) Comparison of cell growth in different parts of breast cancers. Histopathology 17(6): 505-509.
36. Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA (2010a) Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas 39(6): 801-818.
37. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL (2010b) NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39(6): 713-734.
38. Woosley JT (1991) Measuring cell proliferation. Arch Pathol Lab Med 115(6): 555-557.
39. Yang Z, Tang LT, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35(6): 853-860.
40. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 26(18): 3063-3072.